(Alliance News) - Hutchmed (China) Ltd on Monday said that it has completed patient enrolment for the Phase Two registration trial of amdizalisib, its once-a-day oral monotherapy in patients with relapsed or refractory follicular lymphoma.
Hutchmed is a Hong Kong-based commercial-stage, biopharmaceutical company.
The trial is a study designed to test the efficacy and safety of amdizalisib, in patients with relapsed or refractory follicular lymphoma, which is a subtype of non-Hodgkin's lymphoma. It is being conducted in over 35 sites in China.
Hutchmed expects to report topline results on patients in the second half of 2023, followed by the submission of results for presentation at an appropriate medical conference.
If positive, the company plans to apply for marketing authorisation of amdizalisib from the China National Medical Products Administration.
Hutchmed shares were trading 2.8% higher at 273.50 pence each in London on Monday morning.
By Holly Beveridge; Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Hutchmed (HCM)